Examples of using Statistically significant differences in English and their translations into Romanian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
But these are not statistically significant differences.
Statistically significant differences in pulmonary function tests were also observed.
Dichotomous outcomes were compared,of which 59 reported no statistically significant differences.
There were no statistically significant differences between the two Zometa doses.
As the self-esteem, anxiety and depression among the three groups of parents research results indicate statistically significant differences between them.
There were statistically significant differences(p<0.0001) between group 1 and group 2.
Patient demographics andbaseline disease characteristics were well balanced between the treatment groups, and no statistically significant differences were noted.
No statistically significant differences in any other individual Grade 3/4/5 adverse reactions were seen with longer exposure.
In the subset of epilepsy trials, there were no statistically significant differences in the rate of events between lamotrigine and placebo.
Statistically significant differences in efficacy were also observed in each of the 2 individual studies.
Both, the primary(p= 0.92) and secondary endpoints showed no statistically significant differences between efavirenz and nevirapine 200 mg twice daily.
No statistically significant differences were found and no causal relationship with febuxostat was established.
After coadministration with up to 3 mg of dulaglutide at steady state,there were no statistically significant differences on AUC(0-12), Cmax or tmax of paracetamol.
Statistically significant differences are marked(*p< 0.05) for between treatment comparisons(zoledronic acid versus placebo).
The appearance of QT prolongation was similar in all 3 different treatment options,and there were no statistically significant differences between pre- dose and post-dose QTc values.
No statistically significant differences were found between treatment arms in global measures of Quality of Life.
(p =.000), which means that there are statistically significant differences among the three groups of parents, on the level of anxiety.
No statistically significant differences in the overall incidence of bleeding events were observed between Nplate and placebo treated patients.
(p =.648), which means that there are no statistically significant differences among the three groups of parents, on the level of somatization.
Statistically significant differences in patient reported outcomes were observed in favour of patients receiving Picato compared to those receiving vehicle gel.
There were no statistically significant differences observed for the exploratory endpoint of diarrhoea(reported as stool frequency).
Statistically significant differences in amifampridine PK parameters Cmax, AUC0-∞, t1/2 and apparent clearance was observed between fast and slow acetylators at all dose levels.
For both primary endpoints statistically significant differences have been observed for the doses 1 mg/24 h, 2 mg/24 h and 3 mg/24 h in comparison to placebo.
I obtained statistically significant differences between group 1 and group 2 regarding the family environment(p= 0.001) and family socioeconomic status p.
In Study UV I statistically significant differences in favour of adalimumab versus placebo were observed for each component of treatment failure.
In Study UV II, statistically significant differences were observed for visual acuity only, but the other components were numerically in favour of adalimumab.
For both primary endpoints statistically significant differences have been observed for the pramipexole dose groups 0.25 mg, 0.5 mg and 0.75 mg in comparison to placebo.
No statistically significant differences were found between the two treatment groups in Health Related Quality of Life as assessed by FACT-B TOI-PFB scores.
Results: There were statistically significant differences between study group and controls concerning the growth velocity after 3 months of inhaled glucocorticoid therapy(GSI).
For both primary endpoints statistically significant differences have been observed for the pramipexole dose groups 0.25 mg, 0.5 mg and 0.75 mg pramipexole salt in comparison to placebo.